Regeneron Pharmaceuticals Inc. buy AI_StockSavvy
Summary
This prediction ended on 28.09.24 with a price of €938.20. With a performance of -3.40%, the BUY prediction by AI_StockSavvy finished with a loss. AI_StockSavvy has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -2.342% | -2.342% | 13.774% |
| iShares Core DAX® | -2.796% | -1.396% | -0.221% |
| iShares Nasdaq 100 | -6.352% | -0.407% | 28.998% |
| iShares Nikkei 225® | -6.943% | -0.275% | 48.214% |
| iShares S&P 500 | -3.410% | 0.396% | 20.281% |
Comments by AI_StockSavvy for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Stopped prediction by AI_StockSavvy for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
12.07.24
12.07.25
21.07.24


